News

The educational tandem of IDIBELL and the Institut Bellvitge closes the academic year having increased the number of activities and students involved

The educational tandem formed by the Institut Bellvitge and IDIBELL has closed the 2021-2022 academic year with the publication of the fifth issue of Life & Science magazine, the project carried out by 3rd year ESO students and which includes all the activities that the educational center carries out with researchers and professionals from IDIBELL.

Leer más about The educational tandem of IDIBELL and the Institut Bellvitge closes the academic year having increased the number of activities and students involved

An MRI could predict patients with epilepsy who would not suffer cognitive impairment with surgery

A study by IDIBELL, Bellvitge Hospital, and the University of Barcelona identifies, through magnetic resonance imaging, significant differences in the connectivity of several subregions of the hippocampus between patients with epilepsy who, after surgery, suffer impairments in verbal learning and those who do not.

Leer más about An MRI could predict patients with epilepsy who would not suffer cognitive impairment with surgery

Rosa Benet is the new IDIBELL’s managing director

The IDIBELL Board of Trustees approved the appointment of Rosa Benet as the Center’s new Director of Management. Benet is a specialist in financial control with proven experience and responsibilities in multinational environments.

Leer más about Rosa Benet is the new IDIBELL’s managing director

A clinical trial shows positive results for the most common cutaneous lymphoma treatment with an immunosuppressive drug

Dr. Cristina Muniesa and Dr. Octavi Servitje, from the Dermatology Service of the Bellvitge University Hospital (HUB) and IDIBELL researchers, participated in this study that evaluates the use of topical pimecrolimus in mycosis fungoides and was published in the prestigious journal The Lancet Haematology.

Leer más about A clinical trial shows positive results for the most common cutaneous lymphoma treatment with an immunosuppressive drug

The HUB-ICO-IDIBELL biobank renews the ISO 9001:2015 certification

The HUB-ICO-IDIBELL Biobank has renewed the certification for the ISO 9001 standard, a quality standard recognized nationally and internationally based on continuous process improvement, and that demonstrates the organization’s commitment to quality service and customer satisfaction.

Leer más about The HUB-ICO-IDIBELL biobank renews the ISO 9001:2015 certification

Discovered epigenetic alterations associated with the COVID-19 related severe inflammatory syndrome in childhood

Dr. Aurora Pujol from IDIBELL and Dr. Manel Estaller from the Josep Carreras Leukaemia Research Institute identified an epigenetic signature associated to the development of the Multisystem Inflammatory Syndrome in Children (MIS-C) after a SARS-CoV-2 virus infection.

Leer más about Discovered epigenetic alterations associated with the COVID-19 related severe inflammatory syndrome in childhood

A study describes a new way to generate insulin-producing cells

Researchers from the Karolinska Institute in Sweden, in collaboration with Meritxell Rovira from IDIBELL, the P-CMRC, and the UB show that a recently identified molecule stimulates the formation of new insulin-producing cells in zebrafish and in mammalian tissues.

Leer más about A study describes a new way to generate insulin-producing cells

The “Ellas contra la ELA” campaign ends with more than 13.500 euros raised

Today, June 21, World ALS Day, the campaign “Ellas contra la ELA” ends, a women’s football solidarity competition for ALS research.

Leer más about The “Ellas contra la ELA” campaign ends with more than 13.500 euros raised
Scroll to Top